- Home
- STOK vs SVM Comparison
STOK vs SVM Comparison
Compare STOK & SVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- SVM
- Stock Information
- Founded
- STOK 2014
- SVM N/A
- Country
- STOK United States
- SVM Canada
- Employees
- STOK N/A
- SVM N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- SVM Precious Metals
- Sector
- STOK Health Care
- SVM Basic Materials
- Exchange
- STOK Nasdaq
- SVM Nasdaq
- Market Cap
- STOK 997.9M
- SVM 1.1B
- IPO Year
- STOK 2019
- SVM N/A
- Fundamental
- Price
- STOK $19.76
- SVM $4.85
- Analyst Decision
- STOK Strong Buy
- SVM Strong Buy
- Analyst Count
- STOK 6
- SVM 1
- Target Price
- STOK $26.60
- SVM $6.75
- AVG Volume (30 Days)
- STOK 920.7K
- SVM 4.4M
- Earning Date
- STOK 08-12-2025
- SVM 08-07-2025
- Dividend Yield
- STOK N/A
- SVM 0.52%
- EPS Growth
- STOK N/A
- SVM N/A
- EPS
- STOK 0.91
- SVM 0.25
- Revenue
- STOK $199,893,000.00
- SVM $308,064,000.00
- Revenue This Year
- STOK $415.58
- SVM $3.27
- Revenue Next Year
- STOK N/A
- SVM $33.68
- P/E Ratio
- STOK $21.55
- SVM $19.34
- Revenue Growth
- STOK 1218.82
- SVM 35.50
- 52 Week Low
- STOK $5.35
- SVM $2.87
- 52 Week High
- STOK $20.00
- SVM $5.32
- Technical
- Relative Strength Index (RSI)
- STOK 78.62
- SVM 60.21
- Support Level
- STOK $19.07
- SVM $4.50
- Resistance Level
- STOK $19.91
- SVM $4.65
- Average True Range (ATR)
- STOK 1.26
- SVM 0.18
- MACD
- STOK 0.14
- SVM 0.03
- Stochastic Oscillator
- STOK 96.55
- SVM 89.52
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.